Johnson & Johnson (NYSE:JNJ) is Harvey Investment Co. LLC’s 8th Largest Position

Harvey Investment Co. LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 0.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 205,629 shares of the company’s stock after selling 492 shares during the quarter. Johnson & Johnson accounts for approximately 3.4% of Harvey Investment Co. LLC’s investment portfolio, making the stock its 8th largest position. Harvey Investment Co. LLC’s holdings in Johnson & Johnson were worth $29,738,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of JNJ. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $31,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the third quarter worth $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its holdings in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.7 %

Shares of Johnson & Johnson stock opened at $154.22 on Tuesday. The company has a market cap of $371.31 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s 50 day moving average is $147.42 and its 200 day moving average is $156.08. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.22%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Guggenheim upped their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.